SYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998

Category: .

SYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998

Synagis is a respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.
• Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD).
• The safety and efficacy of Synagis have not been established for treatment of RSV disease.
Single-dose liquid solution vials: 50 mg per 0.5 mL and 100 mg per 1 mL.
Manufactured By: MedImmune
Prescribing Information URL: Click Here

Access to SYNAGIS ® (palivizumab) injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.
Palivizumab targets the fusion protein of RSV, inhibiting its entry into the cell and thereby preventing infection. Palivizumab was approved for medical use in 1998.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.